PPHM GRANTED KEY EUROPEAN PATENT FOR ITS CLiNICAL DRUG BAVITIXIMAB

PPHM announced that the European Patent Office(EPO) has granted Patent Number 2,269,656 titled "Selected Antibodies Binding to Aminophospholipids and their Use in Treatment such as Cancer."

This important patent covers Bavi as a combination of matter and for use in treating cancer, including radiotherapy, chemotherapy  and Docetaxel. 

The new patent covers Bavi as a composition matter in antibodies, , antibody drug conjugates. diagnostic and imaging construct and liposomal.